Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study.

Roy S, Lai H, Zouaoui R, Duffner J, Zhou H, P Jayaraman L, Zhao G, Ganguly T, Kishimoto TK, Venkataraman G.

Glycobiology. 2011 Sep;21(9):1194-205. doi: 10.1093/glycob/cwr053. Epub 2011 Apr 22.

PMID:
21515908
2.

Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin.

Liu ZJ, Tian R, Li Y, An W, Zhuge Y, Livingstone AS, Velazquez OC.

Ann Surg. 2011 Sep;254(3):450-6; discussion 456-7. doi: 10.1097/SLA.0b013e31822a72dc.

PMID:
21795970
3.

Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.

Poggi A, Rossi C, Casella N, Bruno C, Sturiale L, Dossi C, Naggi A.

Semin Thromb Hemost. 2002 Aug;28(4):383-92.

PMID:
12244486
4.

Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.

Lee DY, Park K, Kim SK, Park RW, Kwon IC, Kim SY, Byun Y.

Clin Cancer Res. 2008 May 1;14(9):2841-9. doi: 10.1158/1078-0432.CCR-07-0641.

5.

Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.

Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishai-Michaeli R, Bar-Shavit R, et al.

Isr J Med Sci. 1995 Feb-Mar;31(2-3):106-18.

PMID:
7744578
6.

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.

Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, Kennedy TP.

Am J Physiol Cell Physiol. 2010 Jul;299(1):C97-110. doi: 10.1152/ajpcell.00009.2010. Epub 2010 Apr 7.

7.

FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.

Sola F, Farao M, Ciomei M, Pastori A, Mongelli N, Grandi M.

Invasion Metastasis. 1995;15(5-6):222-31.

PMID:
8765197
8.

Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.

Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, Chiu FC, Shackleford DM, Charman SA, Charman WN, Harenberg J, Gonda TJ, Ferro V.

J Med Chem. 2010 Feb 25;53(4):1686-99. doi: 10.1021/jm901449m.

PMID:
20128596
9.
10.

A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.

Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA.

Int J Oncol. 2011 Aug;39(2):401-8. doi: 10.3892/ijo.2011.1040. Epub 2011 May 11.

PMID:
21567086
11.

Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.

Coltrini D, Rusnati M, Zoppetti G, Oreste P, Grazioli G, Naggi A, Presta M.

Biochem J. 1994 Oct 15;303 ( Pt 2):583-90.

12.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

13.

Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.

Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):71-6. Epub 2004 Oct 28.

14.

Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.

Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J.

Cancer Res. 2004 Apr 15;64(8):2743-50.

15.

Inhibition of tumor metastasis by heparanase inhibiting species of heparin.

Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, Peretz T.

Invasion Metastasis. 1994-1995;14(1-6):290-302.

PMID:
7657522
16.

Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin.

Kozlowski EO, Pavao MS, Borsig L.

J Thromb Haemost. 2011 Sep;9(9):1807-15. doi: 10.1111/j.1538-7836.2011.04401.x.

17.

Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro.

Li D, Wang H, Xiang JJ, Deng N, Wang PP, Kang YL, Tao J, Xu M.

Oncol Rep. 2010 Aug;24(2):457-63.

PMID:
20596633
18.
19.

A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.

Chen Y, Peng J, Han M, Omar M, Hu D, Ke X, Lu N.

J Drug Target. 2015 May;23(4):335-46. doi: 10.3109/1061186X.2014.996760. Epub 2014 Dec 26.

PMID:
25541466
20.

Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor.

Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao M, Zheng SZ, Wang AY, Zhang CB, Zhang WW, Lei N.

Biochem Biophys Res Commun. 2009 Aug 21;386(2):374-9. doi: 10.1016/j.bbrc.2009.06.042. Epub 2009 Jun 11.

PMID:
19523924

Supplemental Content

Support Center